AAV Viral Vectors Modulating miRNA for PF-ILD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for progressive fibrosing interstitial lung diseases (PF-ILDs) lack effective disease-modifying therapies, especially for patients with severe liver and kidney problems, and existing treatments like Pirfenidone and Nintedanib have limitations due to side effects and restricted use in patients with severe liver or kidney issues.
Innovation Solution
The use of viral vectors, specifically Adeno-associated virus (AAV) vectors, to modulate microRNA (miRNA) function by delivering miRNA mimetics or anti-miRs to target multiple disease pathways associated with lung fibrosis, thereby slowing or stopping tissue transformation and decline in forced vital capacity in PF-ILDs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments like Pirfenidone and Nintedanib are used for PF-ILD, then disease progression is slowed, but side effects increase and therapeutic efficacy is limited in patients with severe liver or kidney impairment
Solution Approach 1:
The patent changes the mechanism of action from small molecule inhibitors to viral vector-delivered miRNA mimetics, fundamentally altering how the treatment works at the molecular level to achieve disease modification with reduced toxicity
Solution Approach 2:
The patent uses viral vectors as intermediaries to deliver therapeutic miRNA mimetics to target cells in the lung, enabling precise and controlled modulation of fibrotic pathways without the systemic side effects of conventional drugs
2Ease of operation
If conventional small molecule inhibitors are used, then treatment is simple to administer, but multi-target capability is limited and disease modification is insufficient
Solution Approach 1:
The patent designs viral vectors that can simultaneously deliver multiple miRNA mimetics targeting different fibrotic pathways (TGF-β, PDGF, FGF), enabling one treatment to address multiple disease mechanisms and pathways
3Adaptability or versatility
If current pharmacological therapies are used for PF-ILD, then treatment is available, but no approved disease-modifying therapies exist for most PF-ILD patients outside IPF
Solution Approach 1:
The patent develops a universal therapeutic approach using viral vectors that can be adapted to treat different PF-ILD subtypes (IPF, CTD-ILD, sarcoidosis, hypersensitivity pneumonitis) by modifying the miRNA mimetic sequences while maintaining the same delivery mechanism and disease-modifying capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach offers a potential for improved therapeutic efficacy with reduced side effects, enabling multi-targeted therapies that can be administered locally or systemically, including in patients with severe liver and kidney impairments, by modulating miRNAs involved in fibrotic processes, thus addressing the limitations of existing treatments.
Implementation Method 1
The use of viral vectors, specifically Adeno-associated virus (AAV) vectors, to modulate microRNA (miRNA) function by delivering miRNA mimetics or anti-miRs
Implementation Method 2
modulate microRNA (miRNA) function by delivering miRNA mimetics or anti-miRs to target multiple disease pathways associated with lung fibrosis
Data Source
AI summary
Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model.